New Drug Delivery Technologies And QbD Concepts To Be Discussed By Catalent Experts At Forthcoming Events

New Drug Delivery Technologies and QbD Concepts to be Discussed by Catalent Experts at Forthcoming Events

Somerset, NJ – January 24, 2014 —  Experts from Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, are to present on a range of hot drug delivery topics at two forthcoming conferences.

At the 18th Drug Delivery Partnerships meeting in Boca Raton, Florida, Dr. Cornell Stamoran, Vice President Corporate Development & Strategy and Executive Board Member of the Catalent Applied Drug Delivery Institute, will present on two panels, "Improved Patient Outcomes through Better Drug Design: Our Call to Action” and "Designing for Better Outcomes: Turning Concept into Practice" which take place on Tuesday, January 28 th  and Wednesday 29 th respectively. These discussions will address the potential for better patient outcomes through improved drug design, and how the industry can deliver on this promise.

Also at the Drug Delivery Partnerships meeting, Norman Stroud, Catalent’s Director of Technology Development, will present “Softgels: A versatile Drug Delivery System”. His presentation, which takes place on Tuesday, January 28th at 3.30pm in the Innovation Theater, will provide an in depth discussion on the exciting new technologies that are enabling softgel solutions for more molecules, in new markets. This will include the OptiShell® capsule technology that permits semi-solid fills, OptiGel Bio™ technology which offers the oral delivery of macromolecules, and OptiGel Lock™ which provides multi-level abuse deterrence in a softgel dose form. Drug Delivery Partnerships runs from the 27th-29th of January at the Boca Raton Resort & Club, Boca Raton, Florida.

Additionally, Irena McGuffy, Catalent’s Director of Softgel Formulations will present “Enabling Streamlined Pre-Clinical and Clinical Lipid-Based Product Development through the use of In-Vitro and QbD Concepts” at the 3rd Drug Formulation & Bioavailability Conference, which takes place from January 27th to the 29th, at the Hyatt Boston Harbor Hotel in Boston, Mass. The presentation, at 2.20 pm on Wednesday, January 29th, will focus on how the implementation of Quality by Design (QbD) concepts and well designed in vitro screening with Softgel drug delivery technology can rapidly deliver more effective products to market faster. The session will also discuss Catalent’s free FormProRx™ web tool, recently launched to help determine the optimal finished dose suited to specific product requirements.

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit .

More products. Better treatments. Reliably supplied.™